Joo-Hee Kim

Prof. Dr. Joo-Hee Kim

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
DSDae Jin Song
Dae Jin Song
WSWoo Jung Song
Woo Jung Song
JKJae Woo Kwon
Jae Woo Kwon
GKGun Woo Kim
Gun Woo Kim
MKMi-Ae Kim
Mi-Ae Kim
DLDae Hyun Lim
Dae Hyun Lim
Song DJ, et al. Allergy Asthma Immunol Res. 2018 Nov;10(6):591-613. https://doi.org/10.4168/aair.2018.10.6.591

1 April 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
HCHyo Geun Choi
Hyo Geun Choi
JKJoo-Hee Kim
Joo-Hee Kim
JPJi-Young Park
Ji-Young Park
YHYong Il Hwang
Yong Il Hwang
SJSeung Hun Jang
Seung Hun Jang
KJKi-Suck Jung
Ki-Suck Jung

1 January 2021 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
MKMi-Ae Kim
Mi-Ae Kim
YLYong Won Lee
Yong Won Lee
SKSo Ri Kim
So Ri Kim
JKJoo-Hee Kim
Joo-Hee Kim
TMTaek Ki Min
Taek Ki Min
YCYoon-Seok Chang
Yoon-Seok Chang
Kim MA, et al. Allergy Asthma Immunol Res. 2021 Jul;13(4):526-544. https://doi.org/10.4168/aair.2021.13.4.526

1 January 2019 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
MKMin-Hye Kim
Min-Hye Kim
SKSang-Heon Kim
Sang-Heon Kim
SPSo-Young Park
So-Young Park
GBGa Young Ban
Ga Young Ban
JKJoo-Hee Kim
Joo-Hee Kim
YCYou Sook Cho
You Sook Cho
Kim MH, et al. Allergy Asthma Immunol Res. 2019 Jan;11(1):43-54. https://doi.org/10.4168/aair.2019.11.1.43

6 August 2021 in Thorax
Verified
Journal Article
Open access
PDF file
JPJi Young Park
Ji Young Park
JKJoo-Hee Kim
Joo-Hee Kim
ILIn Jae Lee
In Jae Lee
HKHwan Il Kim
Hwan Il Kim
SPSunghoon Park
Sunghoon Park
KJKi-Suck Jung
Ki-Suck Jung
Herd immunity through extensive and rapid vaccination rather than natural immunity acquired by infection is necessary to control a global pandemic like COVID-19. The development of COVID-19 vaccines has been accelerated through government funding and the collaborative efforts of the medical–scientific institutions and the pharmaceutical industry.1 2 In South Korea, the ChAdOx1 nCoV-19 (Oxford/AstraZeneca) and BNT162b2 (Pfizer/BioNTech) vaccines have received emergency approval and are being used. Although the safety and efficacy of these vaccines were established through interim analysis in global clinical trials, long-term data and reports of rare adverse reactions remain inadequate.1 2 We report a case of interstitial lung disease (ILD) after COVID-19 vaccination and review the literature on influenza vaccine-related ILDs. This review is favourable as influenza vaccines are widely administered annually among the elderly, and several vaccine-related ILDs have been reported.

1 January 2019 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
CPChan Sun Park
Chan Sun Park
DKDong Yoon Kang
Dong Yoon Kang
MKMingyu Kang
Mingyu Kang
SKSujeong Kim
Sujeong Kim
YYYoung-Min Ye
Young-Min Ye
KCKorean Registry of Severe Cutaneous Adverse Reactions Consortium
Korean Registry of Severe Cutaneous Adverse Reactions Consortium
Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) to antiepileptic drug (AED), are rare, but result in significant morbidity and mortality. We investigated the major culprit drugs, clinical characteristics, and clinical course and outcomes of AED-induced SCARs using a nationwide registry in Korea. A total of 161 patients with AED-induced SCARs from 28 referral hospitals were analyzed. The causative AEDs, clinical characteristics, organ involvements, details of treatment, and outcomes were evaluated. We compared the clinical and laboratory parameters between SJS/TEN and DRESS according to the leading causative drugs. We further determined risk factors for prolonged hospitalization in AED-induced SCARs. Carbamazepine and lamotrigine were the most common culprit drugs causing SCARs. Valproic acid and levetiracetam also emerged as the major causative agents. The disease duration and hospital stay in carbamazepine-induced SJS/TEN were shorter than those in other AEDs (P< 0.05, respectively). In younger patients, lamotrigine caused higher incidences of DRESS than other drugs (P= 0.045). Carbamazepine, the most common culprit drug for SCARs, was associated with a favorable outcome related with prolonged hospitalization in SJS (odds ratio, 0.12; 95% confidence interval, 0.02-0.63, P= 0.12), and thrombocytopenia was found to be a risk factor for prolonged hospitalization in DRESS. This was the first large-scale epidemiological study of AED-induced SCARs in Korea. Valproic acid and levetiracetam were the significant emerging AEDs causing SCARs in addition to the well-known offending AEDs such as carbamazepine and lamotrigine. Carbamazepine was associated with reduced hospitalization, but thrombocytopenia was a risk factor for prolonged hospitalization. Our results suggest that the clinical characteristics and clinical courses of AED-induced SCARs might vary according to the individual AEDs.